Psoriasis treatments may impact bone health, new study finds
NCT ID NCT07140666
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This completed study looked at 100 adults with moderate-to-severe psoriasis to see how two common biologic drugs, Secukinumab and Adalimumab, affect bone density. Researchers measured bone mineral density in the spine and hip over time. The goal was to understand if these treatments help or harm bone health, since psoriasis itself may raise the risk of osteoporosis.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Secukinumab and Adalimumab
- What this could lead to
- If successful, this could help doctors choose psoriasis treatments that also protect bone health, reducing the risk of osteoporosis.
- What could go wrong
- This is a small, completed observational study, not a treatment trial. Results may not apply to all patients, and it does not test a new drug or cure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chinese PLA General Hosptial
Beijing, Beijing Municipality, 100853, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new gel calm psoriasis Flare-Ups?
- Can a Once-Daily cream tame psoriasis in toddlers?
- Can a switch to guselkumab clear stubborn psoriasis?
- Can a new biologic clear stubborn psoriasis?
- Diet and exercise may tame psoriasis in kids — a trial puts it to the test
- Ancient herbal mix put to the test against psoriasis